Drug intelligence / Profile preview

AVC-S-102

Development stage: Preclinical
Lead developer: Avidicure
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AVC-S-102 is an antibody-drug conjugate (ADC) being developed by Avidicure for the treatment of solid tumors, specifically non-small cell lung cancer (NSCLC) and head and neck (H&N) cancers. It targets the epidermal growth factor receptor (EGFR), a protein frequently overexpressed in these malignancies. By binding to EGFR, AVC-S-102 delivers a cytotoxic payload directly into the tumor cells, aiming to maximize therapeutic efficacy while minimizing systemic toxicity. As of late 2025, the program is in the IND-enabling stage of development.

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on AVC-S-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVC-S-102.

Explore the full profile